Slippery platelet syndromes in subdural hematoma

Platelet function is crucial in preventing intracranial bleeding. However, the role of platelet dysfunction in subdural hematoma (SDH) remains unclear. Prior research has shown that platelet dysfunction can lead to prolonged bleeding times and increased risk of hemorrhage. Yet, the specific contribution of platelet dysfunction to SDH development has not been fully established. This gap motivated the use of platelet function analysis (PFA) to explore its relevance in SDH patients. No prior work had resolved whether SDH is associated with measurable platelet abnormalities. Understanding this could help guide treatment decisions. Platelet dysfunction is known to occur in patients on antiplatelet medications, but its prevalence in SDH is unknown. This study aimed to clarify whether SDH patients exhibit platelet dysfunction and how this might influence clinical outcomes.

The study aimed to assess platelet function in patients diagnosed with subdural hematoma. Researchers sought to determine if platelet dysfunction is common in this patient group and whether it correlates with clinical factors. The motivation stemmed from the lack of data on how platelet dysfunction affects SDH presentation and management. By performing platelet function analysis (PFA), the team aimed to identify patterns of dysfunction. They also wanted to evaluate how antiplatelet medication use influences platelet function in SDH patients. The study aimed to clarify if platelet dysfunction is a contributing factor to SDH severity. Researchers also wanted to assess whether platelet transfusions could correct dysfunction in SDH patients. This work could inform perioperative and postoperative care strategies for SDH patients.

The study included 58 patients with subdural hematoma who underwent platelet function analysis (PFA) at admission. The PFA-100 device was used to measure platelet function using collagen-epinephrine and collagen-ADP assays. Clinical and radiological data were collected for each patient. Platelet function was categorized as normal or abnormal based on PFA results. Researchers compared clinical characteristics between patients with normal and abnormal PFA results. Antiplatelet medication use and comorbidities like hypertension were analyzed for associations with platelet dysfunction. Platelet transfusion effects were evaluated by comparing pre- and post-transfusion PFA results. Data were analyzed statistically to identify significant differences between groups.

Platelet dysfunction was observed in 38% of SDH patients based on PFA results. The collagen-epinephrine assay showed an average of 231 seconds in abnormal cases compared to 118 seconds in normal cases. The collagen-ADP assay averaged 124 seconds in abnormal cases versus 75 seconds in normal cases. Patients with abnormal PFA results were more likely to have hypertension (55% vs. 22%). They were also more likely to use clopidogrel (32% vs. 3%) and antiplatelet medications (59% vs. 22%). No significant differences were found in baseline CT measurements like midline shift or hematoma thickness. Platelet transfusions significantly improved PFA results in dysfunctional patients. These findings suggest a strong link between platelet dysfunction and SDH in certain patient groups.

The study found platelet dysfunction in 38% of SDH patients, as measured by PFA. Patients with abnormal PFA results were more likely to take antiplatelet medications and have hypertension. These findings suggest that platelet dysfunction may contribute to SDH pathophysiology. Platelet transfusions improved PFA results in dysfunctional patients, indicating a potential treatment strategy. The results highlight the importance of assessing platelet function in SDH patients. Antiplatelet use appears to be a significant factor in platelet dysfunction among SDH patients. The findings may impact perioperative management decisions for SDH patients. The study supports the need for further research into platelet dysfunction in traumatic brain injury.